Evidence map›Paper›PMID 36425867›Full record

ArticleEClinicalMedicine2023

STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-refractory patients with unresectable pancreatic cancer: An open label, phase I/IIa trial.

Toshio Fujisawa, Takayoshi Tsuchiya, Motohiko Kato, Masafumi Mizuide, Kazuki Takakura, Makoto Nishimura, Hiromu Kutsumi, Yoko Matsuda, Tomio Arai, Shomei Ryozawa and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EClinicalMedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Current status of endoscopic ultrasound-guided antitumor treatment for pancreatic cancer.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2025
    Review
  5. Article
  6. Clinical immunotherapy in pancreatic cancer.Cancer immunology, immunotherapy : CII · 2024
    Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 2 countries.

Toshio FujisawaDepartment of Gastroenterology, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo, Japan.
Takayoshi TsuchiyaDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Motohiko KatoDivision of Research and Development for Minimally Invasive Treatment, Cancer Center, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Masafumi MizuideDepartment of Gastroenterology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
Kazuki TakakuraDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Jikei University School of Medicine, Minato-ku, Tokyo, Japan.
Makoto NishimuraDepartment of Gastroenterology, Hepatology and Nutrition, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Hiromu KutsumiCenter for Clinical Research and Advanced Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan.
Yoko MatsudaOncology Pathology, Department of Pathology and Host-Defense, Kagawa University, Takamastu, Kagawa, Japan.
Tomio AraiDepartment of Pathology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku, Tokyo, Japan.
Shomei RyozawaDepartment of Gastroenterology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
Takao ItoiDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Hiroyuki IsayamaDepartment of Gastroenterology, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo, Japan.
Hideyuki SayaDivision of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Naohisa YahagiDivision of Research and Development for Minimally Invasive Treatment, Cancer Center, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Keio University · JPJuntendo University · JPSaitama Medical University · JPTokyo Medical University · JPJikei University School of Medicine · JPKagawa University · JPMemorial Sloan Kettering Cancer Center · USShiga University of Medical Science · JPTokyo Metropolitan Geriatric Hospital · JP

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Background: The impact of stroma-targeting therapy on tumor immune suppression is largely unexplored. An RNA oligonucleotide, STNM01, has been shown to repress carbohydrate sulfotransferase 15 (CHST15) responsible for tumor proteoglycan synthesis and matrix remodeling. This phase I/IIa study aimed to evaluate the safety and efficacy of STNM01 in patients with unresectable pancreatic ductal adenocarcinoma (PDAC). Methods: This was an open-label, dose-escalation study of STNM01 as second-line therapy in gemcitabine plus Findings: A total of 22 patients were enrolled, and 3 cycles were repeated at maximum; no DLT was observed. The median OS was 7.8 months. The disease control rate was 77.3%; 1 patient showed complete disappearance of visible lesions in the pancreas and tumor-draining lymph nodes. Higher tumoral CHST15 expression was associated with poor CD3 Interpretation: Locoregional injection of STNM01 was well tolerated in patients with unresectable PDAC as combined second-line therapy. It prolonged survival by enhancing T cell infiltration in tumor microenvironment. Funding: The present study was supported by the Japan Agency for Medical Research and Development (AMED).

Indexed as

5-FU, fluorouracilAMED, Japan Agency for Medical Research and DevelopmentCarbohydrate sulfotransferase 15 (CHST15)CHST15, carbohydrate sulfotransferase 15CI, confidence intervalCS-E, chondroitin sulfate ECTCAE, Common Terminology Criteria for Adverse EventsDCR, disease control rateDLT, dose-liming toxicityECM, extracellular matrixEMT, epithelial mesenchymal transitionEndoscopic ultrasound-guided fine needle injectionEUS-FNI, endoscopic ultrasound-guided fine needle injectionFAS, full analysis setGM-CSF, Granulocyte-macrophage colony-stimulating factorIQR, interquartile rangeIRB, Institutional Review BoardLV, leucovorinMTD, maximum tolerated dosenal-IRI, nanoliposomal irinotecanOS, overall survivalPDAC, pancreatic ductal adenocarcinomaPFS, progression free survivalsCD44v6, soluble CD44 variant 6STNM01TEAE, treatment emergent adverse eventTGF, transforming growth factorTumor-infiltrating CD3+ and CD8+ T cellsUnresectable pancreatic cancer

Identifiers

PMID36425867
PMCPMC9678806
OpenAlexW4309633510

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.